Company ProfilePremium

Pengana International Equities Limited

Company Profile Analysis

Ticker: PIA.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Pengana International Equities Limited - Company showcase

Year Founded & Workforce

2003

3 Employees

Pengana International Equities Limited logo

Pengana International Equities Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Pengana International Equities Limited Overview

Pengana International Equities Limited is a mid-sized Australian listed investment company that gives domestic investors exposure to an ethically screened, actively managed portfolio of global listed equities, packaged with quarterly fully franked dividends. Before 2026 it described itself as the largest international ethical LIC on the ASX. For most of the past decade it has traded at a persistent discount to net tangible assets and underperformed its MSCI World benchmark: the five-year return to July 2025 was 9.3% a year against 16.3% for the index. That record triggered a 2025–2026 governance upheaval. Wilson Asset Management replaced most of the board in October 2025, and the reconstituted board ran a strategic review. That review produced a 12.5-cent special dividend, an equal-access buy-back that retired 58.6% of the share capital at after-tax NTA, and a mandate change to Antipodes' global small- and mid-cap strategy. PIA now enters FY2027 as a much smaller (about A$130 million) vehicle with a new strategy, a refreshed board and an unresolved question about recapitalisation.


Company's own description

In its FY2025 Annual Report, PIA described itself as an Australian LIC whose operating activity is investing Australian capital into global businesses. Its stated corporate objective is to provide shareholders with regular, reliable and fully franked dividends as well as capital growth. The investment strategy under Harding Loevner was to invest in high-quality, growing global businesses to deliver superior risk-adjusted returns. Monthly reports continued to describe PIA as the largest international ethical LIC on the ASX, aiming for capital growth plus regular, reliable, fully franked dividends.

The FY2026 Annual Report repeats this objective. It adds that the portfolio is primarily equities, is currently unhedged, and may use forward FX contracts for risk management. It also frames the Antipodes transition as the next phase of the company.

Business model and "revenue model"

PIA's economics are those of a closed-end fund:

Income sources: dividends from investee companies (A$3.5m in FY2026), interest on custodial cash (A$0.3m), and net realised and unrealised gains on the portfolio (A$10.2m in FY2026). Gains dominate and are fully mark-to-market, so reported "revenue" swings with markets.

Cost base: an external management fee of 1.2% a year (ex-GST, net of reduced input tax credits) of gross portfolio value, payable monthly to PIML. There is also a 15% performance fee on outperformance of the MSCI World Total Return Index (net, AUD), subject to a high-water mechanism. A cumulative underperformance of about A$150.25 million must be recouped before any performance fee becomes payable, equal to roughly A$23.1 million of foregone fees (FY2026 Annual Report, Note 2). Administrative costs (directors' fees, audit, registry, listing, custody, brokerage) were about A$1.0–1.2m a year before FY2026. FY2026 added about A$1.4m of one-off governance costs.

Distribution model: profits are moved to a profit reserve, and quarterly fully franked dividends are paid from it. Franking credits come mainly from Australian tax PIA pays on its realised gains, because its foreign investees provide few franking credits.

Mix: 100% investment income. There is no product, service, subscription or licensing revenue.

Value-chain position, customers and end-markets

PIA sits at the end of the asset-management value chain as the capital pool itself. It outsources portfolio management (to PIML, which sub-delegated to Harding Loevner and now Antipodes), administration (PCG), custody (BNP Paribas), registry (Computershare) and company secretarial work (Acclime).

Its "customers" are its shareholders: 4,734 holders at 29 July 2026, down from 5,055 at 23 July 2025 and about 6,100 in August 2023. Register concentration is high: holders of more than 100,000 shares owned 66.15% of capital in July 2026. The end-market is Australian retail, SMSF and adviser-platform investors seeking offshore equity exposure with franked income, plus activist and discount-arbitrage investors (Wilson Asset Management, Saba Capital) and strategic holders (Washington H. Soul Pattinson).

Independent characterisation

In analytical terms, PIA has been a sub-scale, externally managed global equity LIC whose product proposition (ethical screen plus franked dividends) did not overcome three structural headwinds:

  1. Benchmark-relative underperformance under successive managers.

  2. A management fee (1.2% of gross assets) that is high relative to passive and ETF alternatives.

  3. A persistent discount to NTA, measured at 15.1% to pre-tax NTA at 30 June 2025.

The FY2026 restructuring effectively liquidated about 59% of the vehicle at NTA and re-based the remainder on a higher-alpha-potential small/mid-cap mandate. The investment case is now a bet on Antipodes' stock-picking and on the board's ability to rebuild scale and close the discount.

Strategy

Stated strategy (themes from the FY2026 Annual Report and EGM materials)

  1. Fix the discount and give shareholders choice. The board described the Capital Management Proposal as designed to address the persistent NTA discount and give holders a genuine choice: exit near NTA, or stay invested.

  2. Change manager. Antipodes replaces Harding Loevner, whose performance as sub-manager had, in the board's words, not met expectations. The board chose Antipodes' global small and mid-cap strategy for its disciplined, high-conviction, valuation-focused approach and emphasis on risk management.

  3. Sustain franked income. Quarterly fully franked dividends are to continue, subject to profits and franking capacity. The FY2026 report projects that a 5.60c annual rate could be sustained into FY2027, franked at 25%.

  4. Ongoing discount control. After a stabilisation period, a rolling quarterly buy-back within regulatory limits will be considered.

  5. Rebuild scale. A conditional non-renounceable 1-for-1 rights issue at NTA was proposed, provided the company retained a minimum viable scale. It was deferred on 30 September 2026 pending the reconstituted board's own review.

Initiatives register (last 24 months)

DateInitiativeStatusTarget / metric
21 Aug 2025Leveraged global private credit sleeve via PCG and MercerRejected at AGM, 21 Oct 20254.5% p.a. return over debt cost; dividend up 56% to 8.4c, paid monthly
29 Aug 2025Suspension of on-market DRP-offset buy-backDone (45,000 shares bought before suspension)Not applicable
21 Oct 2025Comprehensive strategic review; proposals invited by 14 Nov 2025Completed March 2026Options covering mandate, manager, capital management and structure
24 Nov 2025Independent Board Committee with insider-proposal protocolsDissolved March 2026Manage WAM-related conflict
Nov 2025Outsourced company secretary (Acclime)DoneIndependence from PCG
FY2026Board fee reduction (Chair 66.9k to 50k; NED 44.6k to 30k)DoneCost discipline
8 May 2026Integrated Capital Management ProposalApproved 27 Jul 2026Exit at after-tax NTA
26 Jun 202612.5c fully franked special dividend (A$32.2m)Paid 19 Aug 2026Distribute franking credits before register change
Jul–Sep 2026Off-market equal-access buy-backCompleted 29 Sep 2026: 58.6% bought back at A$1.2132Not applicable
16 Sep 2026Antipodes appointed as sub-investment managerTransition underwayAntipodes Global SMID strategy
Oct 2026 (deferred)1-for-1 rights issue at NTADeferred 30 Sep 2026Rebuild asset base
Post-stabilisationRolling quarterly buy-backProposedDiscount management
2,026Minimum Viable Entity Threshold testSatisfied (board, 30 Sep 2026)No wind-up resolution

Medium-term financial targets / guidance

PIA gives no earnings guidance; the board states that forecasting profit is difficult given market volatility. The only quantified forward statements are:

  • The capacity to sustain a 5.6c a year fully franked dividend into FY2027.

  • Weekly NTA reporting.

  • The intention (not commitment) to introduce discount-management buy-backs.

ESG commitments are limited to the continuation of the negative-screen ethical framework. Whether the ethical screen carries over unchanged to the Antipodes mandate was not explicitly confirmed in sources reviewed. PCG's March 2026 announcement said PIA would continue to invest in diversified, ethically screened global equities.

Products & Services

PIA issues one security, its ordinary shares. The "product" is the investment exposure those shares provide. The catalogue below covers each element of the shareholder proposition and the underlying strategies.

Top holdings at 30 June 2026 (last disclosed full portfolio under Harding Loevner):

Source: FY2026 Annual Report, unaudited investment schedule. The schedule appears to contain at least one labelling error: a second "Diploma PLC" line carries a JPY code, most likely a Japanese industrial. This is a data-quality observation.

Because the Antipodes SMID strategy targets a different market-cap universe, this mega-cap-heavy portfolio is expected to be largely replaced during the transition. The post-transition holdings were not publicly disclosed as at the research date.

Product Portfolio

OfferingDescriptionKey specificationsTarget investorLaunch / latest versionPricing / fees

PIA ordinary shares (ASX: PIA)

Listed closed-end exposure to a global equity portfolio

106,900,785 shares post-buy-back; daily ASX liquidity; weekly and monthly NTA disclosure

Australian retail, SMSF and adviser platforms

Listed 19 Mar 2004

Brokerage only; underlying 1.2% p.a. management fee on gross portfolio plus 15% performance fee over benchmark

Harding Loevner Global Equity strategy (legacy)

Bottom-up quality-growth global equity, 1989 inception

Four criteria: competitive advantage, quality management, financial strength, sustainable growth; 14-point governance checklist; 38-factor ESG scorecard; benchmark MSCI World TR (net, AUD)

As above

Applied to PIA from May 2021

Within the 1.2% fee

Antipodes Global SMID strategy (new)

Global small and mid-cap equities, Antipodes' pragmatic value approach

Rated "Recommended" by Lonsec and Zenith (per PIA FY2026 Annual Report); detailed PIA-specific mandate parameters not yet published

As above

Transition commencing after 29 Sep 2026

Fee terms of the Antipodes sub-mandate and any IMA amendment: not publicly disclosed in sources reviewed

Ethical screen

Negative screening across 12–13 exclusion categories

Exclusions include adult content, alcohol, non-regulatory animal testing, fossil fuels (GICS 101020), gambling, nuclear, human-rights abuses, UN-sanctioned issuers, GMOs in agriculture, severe ecosystem impact, mining (GICS 151040), tobacco and weapons; materiality generally above 5% of production or 15% of revenue

Values-aligned investors

Since 2004 (Hunter Hall heritage)

Not separately priced

Quarterly fully franked dividend

Regular income from profit reserve and franking account

1.35c a quarter (FY2022–FY2025), 1.40c a quarter from March 2026; franked at 25%

Income-seeking investors

Quarterly payments since c. 2020 (10th consecutive by FY2023)

Not applicable

Special dividend (2026)

One-off 12.5c fully franked

Paid 19 Aug 2026; A$32.2m

All shareholders pre-buy-back

Declared 26 Jun 2026

Not applicable

Dividend Reinvestment Plan

Reinvest dividends into new shares

Historically priced at 5-day VWAP with no discount; suspended for the final FY2026 dividend

Long-term holders

Active FY2022–FY2026

No brokerage

Off-market equal-access buy-back (2026)

Exit at after-tax NTA less costs

Up to 100% of shares; price A$1.2132 (NTA less A$0.0015 costs); 58.6% accepted

All holders at 7 Aug 2026 record date

Approved 27 Jul 2026; completed 29 Sep 2026

Transaction costs A$0.0015 per share

Proposed rolling quarterly buy-back

Ongoing discount control mechanism

Within regulatory limits; subject to solvency and board discretion

Continuing holders

Proposed post-stabilisation; not yet implemented

Not applicable

Conditional 1-for-1 non-renounceable rights issue

Recapitalisation at after-tax NTA

Originally timetabled for October 2026 (ex-date 8 Oct, record 9 Oct); deferred 30 Sep 2026 pending board review

Continuing holders

Deferred

Issue price at NTA (per original terms)

Proposed private credit sleeve (rejected)

Leveraged global private credit fund-of-funds (Mercer-advised, PCG-managed)

Bank loan secured on the equity portfolio; target 4.5% p.a. above cost of debt; PCG to cover any debt-cost shortfall; dividend target 8.4c monthly

Income investors

Proposed 21 Aug 2025; rejected 21 Oct 2025

PCG to receive no management fee but a share of returns above target

HoldingSectorMarket value (AUD K)% of gross assets

Alphabet

Communication Services

15,7134.4

NVIDIA

Information Technology

15,2344.3

Taiwan Semiconductor

Information Technology

14,3054.0

Amazon

Consumer Discretionary

13,9423.9

Samsung Electronics

Information Technology

13,7943.9

Schneider Electric

Industrials

11,6803.3

AMETEK

Industrials

10,0422.8

Johnson & Johnson

Health Care

9,7352.7

ASML

Information Technology

9,5962.7

HEICO

Industrials

9,5052.7

Financial Narrative

All figures in AUD thousands unless stated. FY2022–FY2023 from the FY2023 Annual Report; FY2024–FY2025 from the FY2025 Annual Report; FY2026 from the FY2026 Annual Report and Appendix 4E. Ratios marked "derived" are analyst calculations from audited figures.

Income statement

Notes: The FY2026 ordinary dividends of 5.55c comprise 1.35c (Dec 2025), 1.40c (Mar 2026), 1.40c (Jun 2026) and a 1.40c final declared 26 July 2026 and paid 15 September 2026. Gross profit, operating income and EBITDA are not meaningful for an LIC: there is no cost of sales, depreciation, amortisation or interest expense, so EBITDA is effectively equal to profit before tax.

Margins and growth (derived)

FY2022 margins are left blank because income was negative. Average net assets for FY2022 use 1 July 2021 equity of A$361.8m.

Revenue CAGR: Not meaningful. Total investment income is a market-driven figure that moved from -A$79.4m to +A$14.3m. Measured FY2023 to FY2026, it fell at a 36.5% compound annual rate (derived), which reflects relative underperformance and the market path, not business contraction.

Commentary. The cost structure is the key structural feature. Management fees (about 1.2–1.3% of net assets) absorbed between 8% and 31% of gross investment income in positive years. In FY2026, the A$1.39m of one-off governance costs (AGM 2025 expenses of A$996k and strategic review legal and professional costs of A$395k) pushed total expenses to 2.05% of average net assets, the highest in the five-year window. The inflection is FY2026: the portfolio's total portfolio return (TPR) of 2.1% against an 18.5% benchmark gain (FY2026 Annual Report) caused an 82.3% fall in NPAT, even though global equities were strong.

Balance sheet

Notes: FY2024 after-tax NTA per share is derived (net assets ÷ shares). FY2022 pre-tax NTA was below after-tax NTA because unrealised losses created a deferred tax asset. Working capital is not a meaningful concept: the balance sheet is presented on a liquidity basis, and liquid assets exceed liabilities by more than 7 times in every year.

Post-balance-date pro forma (derived, illustrative): After paying the A$32.2m special dividend (19 Aug 2026), the A$1.40c final dividend (about A$3.6m, 15 Sep 2026) and A$183.3m of buy-back consideration (6–9 Oct 2026), net assets fall to roughly A$129–131m. That is 106.9m shares at an after-tax NTA of about A$1.21, consistent with the A$1.2132 buy-back price.

Cash flow

Note: In an LIC, operating cash flow includes net investment trading, so "free cash flow" is mostly a function of net portfolio selling. It is shown for completeness but should not be read as recurring cash generation.

Commentary. FY2024 stands out for portfolio turnover of about 130% of average investments (A$421.5m of sales), which pushed aggregated turnover to A$116.6m. That disqualified PIA from base-rate entity status for that year and raised its tax rate to 30% (FY2025 Annual Report, Note 3), which explains the elevated 30.3% effective tax rate. The large FY2025 tax payment (A$16.9m) on FY2024 realised gains then rebuilt the franking account from A$3.5m to A$14.4m. That franking capacity is what allowed the board to fund the 12.5c special dividend in 2026 and still project that a 5.6c annual dividend could be sustained into FY2027.

Ratios (derived)

Notes and discrepancies:

FY2025 TPR: the FY2025 Chair's letter reports 12.6% (Directors' Report: 12.56%), but the FY2026 Annual Report states the FY2025 comparative TPR as 11.0%. The two filings conflict; the original FY2025 figure is shown above.

  • Interest coverage, net debt/EBITDA, asset turnover and cash conversion cycle are not applicable because there is no debt, inventory or receivables cycle.

  • Longer-term record: the fund returned 9.3% a year over five years to 31 July 2025, against 16.3% for the index (Capital Brief, citing Pengana data).

Trend commentary

  1. Absolute returns were adequate; relative returns were persistently poor. PIA lagged the MSCI World in every year where both figures are available. The gap widened sharply in FY2026 (-16.4 percentage points), when concentrated AI and mega-cap leadership and a rally in excluded sectors (defence, resources) penalised a diversified, ethically screened quality-growth book. Harding Loevner's style headwinds are acknowledged in the FY2026 Annual Report.

  2. The NTA per share compounded weakly. After-tax NTA rose from A$1.12 (FY2022) to a A$1.37 peak (FY2025), then fell back to A$1.21 (FY2026). The FY2026 decline came from the 12.5c special dividend accrued at balance date (about A$0.125 per share) and weak performance.

  3. The capital base was static until 2026. DRP issuance was largely offset by buy-backs, keeping shares at about 256–258 million for five years. Without primary capital-raising capacity (because of the discount), the fixed-cost base could not be spread over a larger asset pool.

  4. The balance sheet was conservative. No leverage, Level 1 assets only, and full liquidation within one month at 10% of average daily volume (FY2026 Annual Report, Note 14). The rejected private credit proposal would have introduced secured leverage for the first time.

  5. FY2026 was an inflection year. Profit collapsed, governance costs spiked, and the company was then roughly 59% liquidated through the buy-back. FY2027 accounts will reflect a much smaller base, so the fixed-cost ratio will rise unless the vehicle is recapitalised.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Income component (AUD K)

Income component (AUD K)FY2022FY2023FY2024FY2025FY2026

Dividends received (AUD K)

2,0232,3292,8213,2683,542

Interest received (AUD K)

2292395438337

Net gains or losses on financial instruments at FVTPL (AUD K)

-81,37753,11750,14145,99410,244

FX gains or losses on foreign currency cash (AUD K)

2-86-1513

Other operating income (AUD K)

0102142

Total investment income (AUD K)

-79,35055,73153,36349,68714,278

Component share of total investment income (%)

Component share of total investment income (%)FY2023FY2024FY2025FY2026

Dividends (% of total)

4.25.36.624.8

Interest (% of total)

0.50.70.92.4

Net investment gains (% of total)

95.394.092.671.7

Revenue by Segment (%)

GICS sector (% of gross assets)FY2025FY2026

Information Technology (%)

24.327.6

Industrials (%)

17.122.7

Communication Services (%)

15.112.7

Health Care (%)

14.911.9

Financials (%)

11.811.5

Consumer Discretionary (%)

9.68.5

Consumer Staples (%)

1.81.1

Materials (%)

0.90.0

Real Estate (%)

1.10.0

Total equities (%)

96.596.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Group Structure

LayerEntityRole

Board

PIA Board

Governance, capital management, oversight of the IMA

Investment Manager

Pengana Investment Management Limited (AFSL 219462), subsidiary of PCG

Contracted manager under the 2004 IMA; fee recipient

Sub-investment manager (to Sep 2026)

Harding Loevner LP, Bridgewater, New Jersey

Global Equity (quality-growth) strategy

Sub-investment manager (from post-buy-back 2026)

Antipodes Partners Limited, Sydney (Pinnacle affiliate)

Global SMID strategy

Administration

Pengana Capital Group Limited

Financial management, marketing, operations

Company secretary

Acclime Listed Services Australia Pty Ltd (Sandra McIntosh)

ASX and secretarial functions since Nov 2025

Custodian

BNP Paribas (A-1 short-term rating)

Asset safekeeping

Registry

Computershare

Share register, DRP

Auditor

Ernst & Young

Statutory audit

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Total investment income — "revenue" (AUD K)

-79,35055,73153,36349,68714,278

Management fees (AUD K)

4,3673,5564,0254,4604,376

Performance fees (AUD K)

00000

Other operating expenses (AUD K)

1,1619131,1169682,458

Total expenses (AUD K)

5,5284,4695,1415,4286,834

Profit before tax (AUD K)

-84,87851,26248,22244,2597,444

Income tax expense, negative = benefit (AUD K)

-23,22712,90614,59710,4981,454

Net profit after tax (AUD K)

-61,65138,35633,62533,7615,990

EPS basic and diluted (AUD cents)

-24.1414.9613.0813.132.33

Weighted average shares (millions)

255.43256.47257.08257.16257.49

Ordinary dividends declared per share (AUD cents)

5.405.405.405.405.55

Special dividend declared per share (AUD cents)

000012.50

Dividends paid in the year per share (AUD cents)

5.405.405.405.405.50

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Pre-tax margin, PBT / total investment income (%)

—92.090.489.152.1

Net margin, NPAT / total investment income (%)

—68.863.067.942.0

Effective tax rate (%)

27.425.230.323.719.5

Total expenses / average net assets (%)

1.701.491.591.582.05

Management fee / average net assets (%)

1.351.181.251.301.31

Dividend income / average net assets (%)

0.620.780.870.951.06

Balance Sheet and Share Count (millions)

MetricFY2022FY2023FY2024FY2025FY2026

Cash and cash equivalents (AUD K)

10,8349,69814,0428,71013,707

Financial assets at fair value (AUD K)

264,594304,745337,501350,503343,646

Trade and other receivables (AUD K)

4288432796,064342

Tax assets, current plus deferred (AUD K)

12,5917,4813465441

Total assets (AUD K)

288,447322,767351,856365,931357,736

Total debt (AUD K)

00000

Net debt, negative = net cash (AUD K)

-10,834-9,698-14,042-8,710-13,707

Dividend payable (AUD K)

000032,247

Deferred tax liabilities (AUD K)

509,4101,21011,0369,971

Current tax liabilities (AUD K)

0015,61401,680

Total liabilities (AUD K)

9169,91718,92113,13244,361

Total equity / net assets (AUD K)

287,531312,850332,935352,799313,375

Goodwill and intangibles (AUD K)

00000

Issued capital (AUD K)

318,407319,212319,552319,540320,533

Profit reserve (AUD K)

163,823188,337208,082227,958187,541

Retained losses (AUD K)

-194,699-194,699-194,699-194,699-194,699

Shares on issue at year end (millions)

256.03256.84257.17257.17257.98

NTA per share after tax (AUD)

1.121.221.291.371.21

NTA per share before tax on unrealised gains (AUD)

1.081.25—1.411.25

Cash Flow and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Net operating cash flow (AUD K)

16,93011,90917,8788,58018,151

Proceeds from sale of investments (AUD K)

125,46375,537421,503139,655177,777

Purchases of investments (AUD K)

98,01163,289402,072112,486156,567

Income tax paid, negative = refund (AUD K)

6,972-1,564-26416,906226

Capex (AUD K)

00000

Free cash flow, equal to OCF (AUD K)

16,93011,90917,8788,58018,151

Cash dividends paid (AUD K)

12,61612,65312,73512,43513,110

Dividends reinvested via DRP (AUD K)

1,1751,1891,1451,4501,050

Share buy-backs (AUD K)

03848051,46257

Portfolio turnover, sales / average investments (%)

—26.4130.040.651.2

Margin Analysis (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE, NPAT / average equity (%)

-19.012.810.49.81.8

ROA, NPAT / year-end total assets (%)

-21.411.99.69.21.7

ROIC, equal to ROE given no debt (%)

-19.012.810.49.81.8

Equity / total assets (%)

99.796.994.696.487.6

Debt / equity (x)

00000

Liquid assets / total liabilities (x)

300.731.818.627.98.1

Dividend payout, ordinary DPS / EPS (%)

—36.141.341.1238.2

Franking account balance at year end (AUD K)

14,5478,3693,47814,4349,941

Total portfolio return, net (%)

—20.2—12.62.1

MSCI World TR Index, net, AUD (%)

—22.4—14.618.5

Relative return vs benchmark (percentage points)

—-2.2—-2.0-16.4

Total shareholder return excluding franking (%)

—23.3—11.012.9

Revenue by Region

Currency of investments (AUD K)FY2022FY2023FY2024FY2025FY2026

US dollar (AUD K)

184,006211,380249,398235,644234,589

Euro (AUD K)

21,69431,53433,73821,24726,593

Japanese yen (AUD K)

6,03311,63615,10323,47519,995

New Taiwan dollar (AUD K)

000014,305

Hong Kong dollar (AUD K)

19,5609,6238,97214,38013,211

British pound (AUD K)

6,0475,6339,14015,24212,300

Swiss franc (AUD K)

4,6676,1305,6047,1727,287

Swedish krona (AUD K)

10,21812,6827,57612,9435,811

Chinese yuan (AUD K)

498004,9675,685

Canadian dollar (AUD K)

0003,4443,870

Danish krone (AUD K)

2,5874,2752,6932,0860

Indonesian rupiah (AUD K)

4,2578,4592,9502,3400

Brazilian real (AUD K)

2,3653,3931,96100

Singapore dollar (AUD K)

0004,4930

Mexican peso (AUD K)

003663,0700

Polish zloty (AUD K)

1,6910000

Total investments (AUD K)

264,594304,745337,501350,503343,646

Revenue by Region (%)

Region (% of investments)FY2022FY2023FY2024FY2025FY2026

United States dollar listings (%)

69.569.473.967.268.3

Europe incl. UK, Switzerland, Nordics, Poland (%)

17.619.817.416.915.0

Asia-Pacific ex-Japan, HK/CN/TW/ID/SG (%)

9.25.93.57.49.6

Japan (%)

2.33.84.56.75.8

Americas ex-US, Brazil/Mexico/Canada (%)

0.91.10.71.91.1

Capital Markets Data (AUD) and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Share price at 30 June (AUD)

0.8751.025———

NTA after tax at 30 June (AUD)

1.121.221.291.371.21

NTA before tax at 30 June (AUD)

1.081.25—1.411.25

Discount to pre-tax NTA at 30 June (%)

19.018.0—15.1—

Ordinary DPS declared (AUD cents)

5.405.405.405.405.55

Special DPS declared (AUD cents)

000012.50

Shares bought back (millions)

00.420.721.250.05

Valuation Snapshot

MultipleValueComment

Price / after-tax NTA (x)

1.00

By construction at the buy-back price

P/E on FY2026 EPS (x)

52.1

Not meaningful for a mark-to-market LIC

P/E on FY2025 EPS (x)

9.2

Not meaningful

Trailing dividend yield, ordinary 5.55c (%)

4.6

6.1% gross-up at 25% franking (derived)

Analyst Conclusions

Management guidance

PIA gives no earnings guidance. Its explicit forward statements are:

  1. The intention to continue quarterly fully franked dividends, with capacity for a 5.6c annual rate into FY2027.

  2. A board review of capital management alternatives, including the deferred rights issue.

  3. Consideration of a rolling quarterly buy-back after stabilisation.

  4. Completion of the portfolio transition to Antipodes Global SMID.

  5. Recruitment of additional independent directors under Gooch's interim chairmanship.

Consensus growth expectations: none (no analyst coverage identified).

Bull case

  1. Discount structurally addressed. The NTA-priced exit removed the most discount-sensitive sellers. A rolling quarterly buy-back would anchor the price near NTA for continuing holders, a feature few LICs offer.

  2. Better-suited mandate. Antipodes' SMID strategy is independently rated and, according to PIA, award-winning. It gives exposure to a market segment that has lagged mega-caps, so the valuation starting point is more favourable than Harding Loevner's mega-cap quality-growth book offered in 2025–26.

  3. Fee and franking optionality. No performance fee is payable until about A$150m of cumulative underperformance is recouped. Realising the A$9.97m DTL during transition will generate franking credits, supporting the 5.6c dividend.

Bear case

  1. Scale and cost drag. At about A$130m, fixed costs (more than A$1.0m a year before one-offs) plus a 1.2% gross-asset fee push the total expense ratio toward or above 2%. Without a successful rights issue, the vehicle risks a slow death spiral or eventual wind-up.

  2. Manager relationship fragility. PCG retains the IMA to about 2029 and sued PIA months ago. PIA's economics still flow through an intermediary with its own financial pressures (PCG FY2026 net loss of A$5.6m; listed equities outflows of A$232m).

  3. Governance flux. Since October 2025 the board has had three chairs, a near-complete turnover, and its current independence composition and Julian Martin's status are not clearly disclosed. The new director (O'Dea) is linked to both a substantial holder and the manager's parent. Execution of the transition and recapitalisation is therefore uncertain.

Key catalysts and monitorables (next 12 months)

  1. First post-buy-back NTA disclosures and the confirmed post-transition portfolio and holdings.

  2. The board's decision on the rights issue: size, pricing at NTA and take-up.

  3. Disclosure of Antipodes sub-mandate fee terms and any IMA amendment with PIML/PCG.

  4. Launch and parameters of the rolling quarterly buy-back.

  5. New independent director appointments; board composition and gender diversity.

  6. The updated substantial-holder register (WAM, WHSP, Saba, PCG post-buy-back).

  7. The 2026 AGM: re-election votes and any spill or structural resolutions.

  8. H1 FY2027 results (February 2027), the first under the Antipodes strategy, including transition costs and tax.

  9. Whether the ethical screen is formally retained.

  10. Final disposition of Takeovers Panel matter TP26/063.

Analyst verdict

Pengana International Equities has spent most of its 22-year life demonstrating the core weakness of the externally managed listed investment company: when performance lags, the discount widens. When the discount widens, capital cannot be raised. When capital cannot be raised, fixed costs bite harder. Under Harding Loevner, PIA earned respectable absolute returns (20.2% in FY2023, 12.6% in FY2025) but consistently trailed the MSCI World, catastrophically so in FY2026 (2.1% against 18.5%). Its manager-aligned board's response in 2025, a leveraged private credit sleeve, was correctly rejected by shareholders as a solution to the wrong problem.

What followed was messy but, on balance, value-accretive for shareholders. The Wilson-led board delivered what activists typically seek: a fully franked special dividend that distributed trapped franking credits, and a buy-back at after-tax NTA less only 0.15 cents of costs. Holders of 58.6% of the shares took that exit, receiving about A$183m at effectively full value. The cost was about A$1.4m of governance expenses, litigation with the manager's parent and a period of acute board instability.

The continuing entity is a different proposition: a roughly A$130m vehicle with a new small/mid-cap mandate run by a well-regarded manager, an ungeared balance sheet, adequate franking for its dividend, and an explicit intention to manage the discount mechanically. Those are genuine positives. But the company is now sub-scale, its fee arrangements with the Antipodes sub-mandate are undisclosed, it still has a contract to 2029 with a recent litigant, and its board is interim and incompletely disclosed.

Verdict: PIA is now an execution story, not a value-unlock story; the value unlock has already been paid out. For continuing holders, the investment merit depends almost entirely on three verifiable events in the next 12 months: a credible recapitalisation, transparent and competitive fee terms, and the early track record of the Antipodes SMID book. Until those are evidenced, a neutral stance is warranted, and the vehicle carries elevated wind-up or merger optionality.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

DirectorRoleAppointedBackgroundIndependence

Francis (Frank) Gooch, B.Bus, CPA

Interim Chair

Re-appointed 16 Sep 2026 (previously director 5 Jun 2017–16 Feb 2026; Chair from 6 Dec 2017)

Former MD of Milton Corporation (CEO 1999, MD 2004–2018); 11 years at Macquarie Bank; former chair of the Australian Listed Investment Companies Association

—

Brendan O'Dea

Non-executive director

16 Sep 2026

CIO of Washington H. Soul Pattinson (appointed Oct 2021, per 2023 press reporting); former MD and CEO of Milton Corporation; 22 years at Citigroup (Sydney, Hong Kong, New York, Tokyo); non-executive director of Pengana Capital Group since April 2023

—

Richard Caldwell, BEc/LLB, Grad Dip Applied Finance

Independent NED; Chair of Audit, Risk & Compliance Committee

21 Oct 2025

Senior roles at Citibank Sydney, JP Morgan London and Tricom; listed directorships including Southern Hemisphere Mining (ASX: SUH) and Greatcell Solar

Independent

Julian Martin, B.Ec, Harvard OPM, MAICD

Independent NED

21 Oct 2025

Founding CEO of Mojo New York; co-founder of Chiat/Day/Mojo London; Executive Director at BBH London; SecondBite Chair 2020–2023

Independent. Status uncertain: the 16 Sep 2026 release said he would resign on 29 Sep 2026, but the 30 Sep 2026 release listed only Jollie, Wilson and Hamilton as resigning.

Board of Directors — Brett Jollie

DirectorRoleTenureExit

Brett Jollie

Independent NED (from 27 Nov 2025); Chair (16 Feb–29 Sep 2026)

10 months

Resigned 29 Sep 2026. Background: 23 years at Aberdeen Asset Management (14 as Australian CEO); former CEO of Hearts & Minds Investments; appointed CEO of U Ethical on 7 Apr 2026.

Geoff Wilson AO

Non-independent NED

21 Oct 2025–29 Sep 2026

Resigned after buy-back. Founder of Wilson Asset Management (1997); chairs eight WAM LICs.

Jesse Hamilton, CA

Non-independent NED

21 Oct 2025–29 Sep 2026

Resigned. CFO of Wilson Asset Management (International).

Russel Pillemer

Managing Director

5 Jun 2017–21 Oct 2025

Removed by shareholders

David Groves

Non-independent NED

13 Jan 2017–21 Oct 2025

Removed by shareholders; former independent Chair of PCG

Sandi Orleow, CFA

Independent NED; ARCC Chair

1 Sep 2019–21 Oct 2025

Removed by shareholders

Directors' Remuneration

Director (FY2026)Fees (AUD)Superannuation (AUD)Total (AUD)

Frank Gooch

42,0005,04047,040

Brett Jollie

22,5452,70525,250

Julian Martin

18,7302,24820,978

Richard Caldwell

18,7302,24820,978

Sandi Orleow

15,7501,89017,640

David Groves

15,680015,680

Geoffrey Wilson

6,2447496,993

Jesse Hamilton

6,2447496,993

Total

145,92315,629161,552

Board fee schedule (AUD, incl. super)

FY2022

FY2023

FY2024

Chair fee (AUD)

66,00066,30066,600

Independent NED fee (AUD)

44,00044,20044,400

Total board remuneration (AUD)

154,000154,700160,950

Major Shareholders

HolderShares%

Wilson Asset Management Group

30,528,45911.83

Saba Capital Management GP, L.L.C.

25,617,0019.94

Washington H. Soul Pattinson and Company Limited

24,470,5809.51

Major Shareholders by Rank

RankHolderShares%
1

WHSP Holdings Pty Ltd

24,470,5809.49
2

WAM Strategic Value Limited

23,028,4598.93
3

Citicorp Nominees Pty Ltd (likely including Saba)

21,455,7528.32
4

BNP Paribas Nominees Pty Ltd

9,245,5263.58
5

Netwealth Investments Limited

7,457,6872.89
6

HSBC Custody Nominees (Australia) Limited

6,659,6042.58
7

BNP Paribas NOMS Pty Ltd

4,256,9921.65
8

Morgan Stanley Australia Securities (Nominee)

3,964,1051.54
9

Pengana Capital Ltd

3,454,8151.34
10

Netwealth Investments Limited (second account)

3,028,4171.17

Competitive Landscape

Key Competitors

#CompetitorVehicle typeRelevance to PIA
1

WAM Global Limited (ASX: WGB)

Global equity LIC (Wilson Asset Management)

Direct LIC peer; manager-affiliated with PIA's 2025–26 activist; allegedly proposed a combination with PIA

2

MFF Capital Investments (ASX: MFF)

Global equity LIC (concentrated quality)

Largest-scale global LIC comparator

3

Future Generation Global (ASX: FGG)

Global fund-of-managers LIC (philanthropic)

Retail global LIC; Wilson-founded

4

Hearts and Minds Investments (ASX: HM1)

Global high-conviction LIC

Former CEO Brett Jollie served on PIA's board

5

Platinum Capital (ASX: PMC)

Global equity LIC

—
6

Magellan Global Fund (ASX: MGF)

Listed global equity fund

—
7

Antipodes Global Shares (Quoted Managed Fund)

Active ETF / QMF

Same manager as PIA's new mandate; trades near NAV, a structural competitor

8

Hyperion Global Growth Companies (Managed Fund) / Magellan / other active global ETFs

Active ETFs

NAV-priced alternatives that remove discount risk

9

Vanguard MSCI Index International Shares ETF (ASX: VGS) and iShares/BetaShares global ETFs

Passive ETFs

Low-cost benchmark exposure; PIA's main structural threat

10

Ethical global ETFs (e.g. BetaShares Global Sustainability Leaders, ETHI)

Passive ethical ETFs

Direct substitute for PIA's ethical proposition

11

Pengana Harding Loevner International Fund

Unlisted managed fund

In-house sister product (same strategy to 2026)

Peer Comparison FY2026

MetricPIA FY2025PIA FY2026

Net assets (AUD Mn)

352.8313.4

Total portfolio return (%)

12.62.1

Benchmark return (%)

14.618.5

Total expenses / average net assets (%)

1.582.05

Management fee rate on gross portfolio (%)

1.201.20

Ordinary DPS (AUD cents)

5.405.55

Discount to pre-tax NTA at year end (%)

15.1—

R&D intensity (%)

00

Recent Developments

There were no layoffs or hiring (no employees), no product launches and no regulatory enforcement actions beyond the ASX query and the Takeovers Panel application.

Company Snapshot

3

Employees

2003

Founded

Sydney, Australia

Headquarters

SWOT Analysis

Strengths

  • Ungeared, fully liquid balance sheet. Zero borrowings FY2022–FY2026; 100% Level 1 assets; the portfolio could be liquidated within one month (FY2026 Annual Report, Note 14).
  • Dividend record. Quarterly fully franked dividends through COVID; the 10th consecutive quarterly dividend was paid by FY2023; the rate rose from 1.35c to 1.40c in March 2026.
  • Franking capacity. A$9.9m franking balance at 30 June 2026, plus a A$9.97m deferred tax liability that converts to franking credits on realisation (FY2026 Annual Report, Note 12).
  • Discount closed for exiting holders. The NTA-priced buy-back (A$1.2132) let 58.6% of shares exit at NTA less 0.15c of costs.
  • Board alignment improved. Three of five directors were independent by June 2026 (versus two of four before October 2025); manager-affiliated directors were removed; fee rates were cut 25–33%.
  • Manager quality. Antipodes' SMID strategy is rated "Recommended" by Lonsec and Zenith, and PIA's report describes the firm as Morningstar's 2026 Fund Manager of the Year.

Weaknesses

  • Chronic underperformance. 9.3% a year against 16.3% for the index over five years to July 2025; FY2026 TPR of 2.1% against 18.5%.
  • Fee drag. A 1.2% management fee on gross assets; total expenses of 2.05% of average net assets in FY2026.
  • Dividends not covered by income. FY2026 EPS of 2.33c against 5.55c of ordinary dividends declared (payout of about 238%); dividend income of A$3.5m against A$13.1m paid in cash.
  • Scale loss. Shares fell from 257.98m to 106.90m, so fixed costs (registry, audit, listing, board) weigh more than twice as heavily per dollar of NTA.
  • Disclosure-control lapses. ASX query over the AFR pre-release (August 2025); FY2026 report errors (relabelled FY2025 currency comparatives, a "27 November 2026" date, a mislabelled holding).
  • Manager succession instability. Three portfolio regimes in about nine years: Pengana in-house (2017–2021), Harding Loevner (2021–2026), Antipodes (2026–).

Opportunities

  • Rights issue at NTA. A recapitalisation could restore scale if the Antipodes strategy attracts demand.
  • Rolling quarterly buy-back. Could structurally cap the discount.
  • SMID valuation rebound. Global small and mid-caps could rebound after a long period of mega-cap concentration; PIA's own monthly reports commented on the US–international valuation gap.
  • Performance-fee headroom aligns the manager. The A$150.25m cumulative underperformance hurdle means no performance fee until substantial outperformance is recovered.
  • Higher look-through ownership for strategic holders. If WHSP and PCG did not tender, their holdings roughly double (derived). That could support a future corporate solution such as a merger or an internalised mandate.
  • IMA renegotiation. The settlement and board reset create an opening to revisit the 1.2% fee and the 2029 term.

Threats

  • Sub-scale wind-up or merger risk. The board confirmed the Minimum Viable Entity Threshold was met, but further attrition could reopen the question.
  • Manager relationship risk. PCG litigated against PIA in 2026; settlement terms were not publicly disclosed in sources reviewed.
  • Activist cycling. Saba Capital (9.94% pre-buy-back) is a known closed-end-fund activist.
  • Transition costs and tax. Turning over a mega-cap book into SMID names will crystallise gains (the A$9.97m DTL) and brokerage costs.
  • Currency. A 15% AUD move would swing pre-tax profit by about A$51.5m on the June 2026 book (proportionally less after the buy-back); the portfolio is unhedged.
  • ETF substitution. NAV-priced active and ethical ETFs offer similar exposure without discount risk.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
23 Jul 2025Register shows WHSP 11.95%, Saba 9.96%, WAM 8.45%Activist and strategic holders reach a blocking position
21 Aug 2025FY2025 results: NPAT A$33.8m, EPS 13.13c; private credit proposal launchedStrategic pivot proposed by manager-aligned board
21 Aug 2025ASX query over AFR article published before the announcementDisclosure-control weakness; PIA commits to update its continuous disclosure policy
29 Aug 2025DRP-offset on-market buy-back suspendedNot applicable
Late Aug / Sep 2025WAM Strategic Value notice to remove Pillemer, Groves and OrleowStart of proxy contest
4 Sep 2025Shareholder webinar on private credit proposalNot applicable
15 Sep 2025FY2025 final dividend of 1.35c paidNot applicable
21 Oct 2025AGM: private credit rejected (proxies about 59.65% against); three directors removed; four WAM nominees elected; strategic review launched; share price up about 2.4% to A$1.26Change of control of the board
21 Oct 2025PCG says it remains manager under an IMA running to March 2029Sets up the manager-versus-board conflict
14 Nov 2025Deadline for strategic review proposalsNot applicable
24 Nov 2025IBC established after a proposal from WAM-associated companiesConflict management
27 Nov 2025Brett Jollie appointed; Acclime company secretaryGovernance strengthening
16 Dec 20251.35c quarterly dividend paidNot applicable
16 Feb 2026Half-year results: NPAT A$4.6m (H1 FY2025: A$26.9m); discount narrowed from 15.1%; Gooch retires; Jollie becomes Chair; dividend lifted to 1.40cPerformance weakness; dividend increase
5 Mar 2026PCG announces Antipodes "assist" agreement; PIA trading haltManager acting unilaterally
6 Mar 2026PIA says PCG's announcement was made without board or IBC consentOpen dispute
Mar 2026IBC completes review and is dissolved; March NTA performance -5.5% against index -2.6%Not applicable
16 Mar 20261.40c dividend paidNot applicable
23 Apr 20261.40c quarterly dividend declared (ex-date 29 May 2026)Not applicable
8 May 2026Capital Management Proposal and Antipodes endorsement announcedStrategic resolution path
21 May 2026April report: PIA +4.4%, in line with indexNot applicable
16 Jun 20261.40c dividend paidNot applicable
26 Jun 202612.5c special dividend declared; EGM notice (no IER; BJO Custodians as adviser)Not applicable
17 Jul 2026Pre-tax NTA A$1.34; June report releasedNot applicable
27 Jul 2026EGM approves buy-back (65.06% for, 33.47% against); 1.40c final dividend declaredShareholder mandate
28–29 Jul 2026PCL announces, then serves, NSW Supreme Court proceedings alleging undisclosed conflictsLitigation risk
7 Aug 2026Buy-back record date; after-tax NTA 123.92cNot applicable
12 Aug 2026Buy-back booklet issued (up to 257,975,845 shares)Not applicable
19 Aug 2026Special dividend paid (A$32.2m)Not applicable
26 Aug 2026PCG FY2026 results: FUM A$4,069m, net loss A$5.6m; discloses PIA no longer an associateManager under financial pressure
31 Aug 2026PIA FY2026 results: NPAT A$6.0m (-82.3%); TPR 2.1% against 18.5% index; NTA A$1.21Weak result
31 Aug–1 Sep 2026PCG Takeovers Panel application (TP26/063) seeking interim orders against buy-back and rights issueEscalation
11 Sep 2026Panel decides to conduct proceedings; after-tax NTA 119.72cNot applicable
15 Sep 20261.40c final dividend paidNot applicable
16 Sep 2026Settlement; Antipodes appointed; Gooch and O'Dea join boardDispute resolved
21–24 Sep 2026Buy-back closes; withdrawal window extended to 24 SepNot applicable
25 Sep 2026Buy-back calculation dateNot applicable
29–30 Sep 2026151.1m shares cancelled at A$1.2132; three directors resign; rights issue deferred; Minimum Viable Entity Threshold metVehicle shrinks about 59%
6–9 Oct 2026Buy-back payments of about A$183.3mNot applicable

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Revenue by Segment (%): Total equities to Health Care: Total equities fell from 96.5% in FY2025 to 96.1% in FY2026.
Pengana International Equities Limited — Revenue by Segment (%): Total equities to Health Care
Series (%)FY2025FY2026
Total equities96.596.1
Information Technology24.327.6
Industrials17.122.7
Communication Services15.112.7
Health Care14.911.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. PIA Annual Report and Appendix 4E, year ended 30 June 2026 (released 31 Aug 2026) (investorpa.com)
  2. PIA Annual Report, year ended 30 June 2025 (pengana.com)
  3. PIA Appendix 4E and Annual Report, year ended 30 June 2023 (announcements.asx.com.au)
  4. PIA Appendix 4E, year ended 30 June 2022 (announcements.asx.com.au)
  5. PIA ASX release, Response to PCG announcement and trading halt update (6 Mar 2026) (announcements.asx.com.au)
  6. PIA Notice of EGM (26 Jun 2026) (announcements.asx.com.au)
  7. PIA 2025 AGM announcement (21 Oct 2025) (announcements.asx.com.au)
  8. PIA FY2026 results Chair letter (31 Aug 2026) (bulletin.webull.com)
  9. PIA Investor Presentation and Chair Letter, half year to 31 Dec 2025 (pengana.com)
  10. PIA Monthly reports (Feb, Mar, Apr, Jun 2026) · report.pengana.com · report.pengana.com · bulletin.webull.com
  11. PCG FY2026 Appendix 4E and Annual Report (investorpa.com)
  12. Takeovers Panel, TP26/063 (1 Sep 2026) (takeovers.gov.au)
  13. Sharecafe, settlement and Antipodes appointment (16 Sep 2026) (sharecafe.com.au)
  14. Sharecafe, buy-back completion and board changes (30 Sep 2026) (sharecafe.com.au)
  15. Money Management, settlement (Sep 2026) (moneymanagement.com.au)
  16. Money Management, Takeovers Panel application (Sep 2026) (moneymanagement.com.au)
  17. Kalkine, EGM approval and legal threat (Jul 2026) (kalkine.com.au)
  18. Kalkine, PCG standoff (Jul 2026) (kalkine.com.au)
  19. Kalkine, buy-back record date (kalkine.com.au)
  20. Kalkine, buy-back booklet (kalkine.com.au)
  21. Kalkine, weekly NTA (11 Sep 2026) (kalkine.com.au)
  22. Kalkine, weekly NTA (7 Aug 2026) (kalkine.com.au)
  23. Kalkine, capital management plans (May 2026) (kalkine.com.au)
  24. AdviserVoice, Antipodes appointment (May 2026) (adviservoice.com.au)
  25. Capital Brief, PIA denies changes to management arrangements (6 Mar 2026) (capitalbrief.com)
  26. Capital Brief, Antipodes "assist" agreement (capitalbrief.com)
  27. Capital Brief, WAM removal notice (capitalbrief.com)
  28. Capital Brief, AGM outcome (capitalbrief.com)
  29. Capital Brief, share price reaction to AGM (capitalbrief.com)
  30. Investor Daily, private credit rejection (Oct 2025) (investordaily.com.au)
  31. Financial Standard, Pengana threatens legal action (28 Jul 2026) (financialstandard.com.au)
  32. FilingReader, FY2026 results summary (filingreader.com)
  33. FilingReader, Jollie appointment (27 Nov 2025) (filingreader.com)
  34. InvestSMART, dividend announcement (23 Apr 2026) (investsmart.com.au)
  35. StockAnalysis, PIA quote and profile (stockanalysis.com)
  36. MarketIndex, PIA corporate details (marketindex.com.au)
  37. MarketIndex, Brendan O'Dea director profile (marketindex.com.au)
  38. Financial Newswire, PCG board changes (O'Dea background) (financialnewswire.com.au)
  39. FinancialFilings, PIA identifiers (ISIN, LEI) (financialfilings.com)
  40. Pengana, Harding Loevner appointment (pengana.com)
  41. Money Management, Harding Loevner appointment (2021) (moneymanagement.com.au)
  42. Pengana, Hunter Hall fund strategy update (2017) (pengana.com)
  43. Investor Daily, Pengana revamps Hunter Hall funds (2017) (investordaily.com.au)
  44. Investor Daily, FY2018 profit (16 Aug 2018) (investordaily.com.au)
  45. Strawman, PIA history summary (strawman.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.